Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.

Inclusion Criteria: * written informed consent (for individuals under 18 written informed consent of parents is required); * age between 12 and 26 years; * UHR as classified by the CAARMS (Yung et al., 2005); * genetic diagnosis of 22q11DS Exclusion Criteria: * acute suicidal behaviour (score of 6 on CAARMS item 7.3) or aggressive behaviour (score of 6 on CAARMS item 5.4); * Drug abuse that contributed decisively to the presentation of the index episode, (dependency on morphine, cocaine, amphetamine, but not THC); * Alcohol abuse if considered as major problem; * Epilepsy; 5./IQ\<70); * Pregnancy and lactation; * Previous history of antipsychotic drug treatment (\> one week treatment); * Laboratory values more than 15% outside the normal range for transaminases, CRP or bleeding parameters; * Individuals with organic brain syndrome; * Individuals who are taking anticoagulants; * Individuals who are taking omega-3 supplements, currently or within 8 weeks of being included in the trial; * Individuals who have other, severe, intercurrent illness which in the opinion of the investigator may put them at risk or influence the results of the trial.